Navigation Links
Hagens Berman Sobol Shapiro Investigating CellCyte
Date:1/9/2008

SEATTLE, Jan 9 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP (http://www.hbsslaw.com/cellcyte.htm) today announced it is investigating the business practices of CellCyte (OTC Bulletin Board: CCYG) for potential violations of securities laws.

The investigation comes after CellCyte's shares plunged 55 percent after news reports detailed alleged discrepancies in CellCyte CEO Gary Reys' educational and professional credentials.

CellCyte's stock dropped after the company made changes to its Web site concerning Reys' claims to have attended University of Washington and to be a certified public accountant. Media reports also call into question other claims made by Reys concerning his role in other business ventures.

According to published media reports, the changes were prompted by calls from Seattle media questioning the veracity of Reys' claims.

If you are an investor in CellCyte, have information concerning this investigation or if you have any questions concerning CellCyte's actions, please contact plaintiff's counsel at 206-623-7292 or e-mail the law firm at info@hbsslaw.com. You can view additional materials on this investigation at http://www.hbsslaw.com/cellcyte.htm.

Hagens Berman Sobol Shapiro, a law firm with offices in Seattle, San Francisco, Los Angeles, Boston, Chicago and Phoenix, is active in major litigations pending in federal and state courts throughout the United States and has taken a leading role in many important actions on behalf of defrauded investors, consumers, and companies, as well as victims of human rights violations. The Hagens Berman Web site (http://www.hbsslaw.com) has more information about the firm.

Contact: Hagens Berman Sobol Shapiro LLP

206-623-7
'/>"/>

SOURCE Hagens Berman Sobol Shapiro LLP
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp. of Washington
4. CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... Shire plc (LSE: SHP, Nas...cal company, today announced a voluntary recall of...lot of the Attention-Deficit/Hyperactivity Disorde...his action because some Daytrana patches do not me...er removal specification, and as a result, patient...
(Date:12/3/2009)...c. 3 Caliper Life Scienc...ools and services for drug discovery and life scie...oftware for IVIS® in vivo imaging systems. Li...er IVIS systems currently installed in laboratorie...ectral unmixing tools to enhance fluorescent sensi...
(Date:12/2/2009)...c. 2 Spectrum Blue Steel is emergi...anies on the planet. Through the efforts of True G...t and Recycling Specialist Leroy Johnston, who has... stated that Spectrum Blue Steel is light years ah...acular earnings because of the bi products recover...
(Date:12/2/2009)... Reportlinker.com announces that a...talogue: ,, Drug Discovery Technologies - A Gl...,, http://www.reportlinker.com/p0164246/Drug-D...Trends--Opportunities.html ,, Drug discovery h... pharmaceutical company,s business strategy. There...
Breaking Biology Technology:Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9
... is Cepheid,s Second FDA Cleared Diagnostic Test i...n Twenty-Four Hours Over Conventional ...t. 1 Cepheid (Nasdaq:,CPHD) today announced it ha...inistration (FDA) to market its Xpert(TM) MRSA/SA ...rt(R) System, for the detection of,Methicillin-res...
... October 1 , - "Expert Consult" Title Regularly I... Always Current, Elsevier, the leading publisher ... publication of the 40th edition of the most famou...y: The Anatomical Basis of Clinical,Practice ( htt...0443066849 ),in September 2008., In celebration o...
...if., Oct. 1 Lumiphore, Inc., a,biotechnology lead...nt,metal-lanthanide technology for use in high-val...xclusive agreement with Biophor Diagnostics, Inc.,...ts in diagnostic tests,for drugs of abuse., Under...usive worldwide,rights to Lumi4(TM) technology in ...
Other Biology Technology:Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures 2Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures 3Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures 4Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures 5New 40th Edition of Gray's Anatomy Celebrates 150 Years as the World's Preeminent Anatomical Reference 2New 40th Edition of Gray's Anatomy Celebrates 150 Years as the World's Preeminent Anatomical Reference 3Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board 2
(Date:12/2/2009)...ntain forest,s woodland herb population has shown ...ories recover from logging, according to Purdue Un...rtions of the forest nearly 80 years ago, the dist...t floor was similar to that of undisturbed areas. ...orestry and natural resources, said that contrasts...
(Date:12/2/2009)...nter researchers have figured out how stem cells i...able to resist radiation therapy. And using a drug...cancer stem cells, they were able to kill many mor...riment. , The work builds off earlier research ...ects of radiation much better than other cancer ce...
(Date:12/2/2009)...roduct called moist snuff placed between lip and ...obacco industry to change manufacturing practices ...udy is published online in ACS, monthly journal C...his category of tobacco products contains surprisi...ng substances. Called polycyclic aromatic hydrocar...
Breaking Biology News(10 mins):Study finds logging effects vary based on a forest's history, climate 2Discovery makes brain tumor cells more responsive to radiation 2INV102 Asthma Product Discussed at the European Respiratory Society 14206 1INV102 Asthma Product Discussed at the European Respiratory Society 14206 2ESMO recognizes centers of excellence in palliative care for cancer patients 57956 1ESMO recognizes centers of excellence in palliative care for cancer patients 57956 2NKTR 102 Shows Encouraging Anti Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplin 5029 1NKTR 102 Shows Encouraging Anti Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplin 5029 2NKTR 102 Shows Encouraging Anti Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplin 5029 3NKTR 102 Shows Encouraging Anti Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplin 5029 4NKTR 102 Shows Encouraging Anti Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplin 5029 5
..., Nitrogen pollution from agriculture and fossil ... in the UK. A new European study is starting to sh... current policies to protect ecosystems may need a...in 2004, her findings were so significant they wer...elected as contributing to one of the top ten scie...
..., Athens, Ga. For the estimated millions of AIDS...oping resistance to currently available medicines,... may offer a new treatment option by targeting a p... responsible for the devastating disease. , Appr...ectious viral disease known as HIV-AIDS. Although ...
..., WALNUT CREEK, -The genome analysis of a tiny gr...uniquely associated with carbon dioxide capture an...es revealed in the study are those that encode the...le that houses the photosynthetic apparatus, the c...ght to chemical energy. The genome also provides ...
Other Biology News:Nitrogen -- the silent species eliminator 2Nitrogen -- the silent species eliminator 3New class of drug offers hope to treatment-resistant AIDS patients 2New class of drug offers hope to treatment-resistant AIDS patients 3Green alga genome project catalogs carbon capture machinery 2Green alga genome project catalogs carbon capture machinery 3
Mouse Anti-Keap1 Monoclonal Antibody, Unconjugated, Clone 333116 from R&D Systems
Anti-Myelin Basic Protein (MBP), aa 129-138 Monoclonal Antibody, Unconjugated, Clone clone 1 from CHEMICON
Normal Guinea Pig Serum from Equitech-Bio
ELF 97 Cytological Labeling Kit *with streptavidin alkaline phosphatase conjugate* *50 assays* from Molecular Probes (Invitrogen)
Biology Products: